RSV Archives
RSV-HRV viral interference
May. 15, 2017—RSV infection reduces the risk of infection with human rhinovirus, which could have implications for vaccine development and prevention strategies for viral respiratory tract infections in infants.
Team isolates new antibodies that may aid RSV vaccine design
Feb. 9, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
Research sheds light on how RSV wards off potential vaccines
Oct. 20, 2016—Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.
Team to study RSV’s role in asthma formation
Jul. 21, 2016—Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).
Gene variant, environment can boost RSV severity
Apr. 2, 2015—A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found.
Respiratory viruses are main childhood pneumonia culprit: Study
Feb. 26, 2015—Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine.
Study identifies antibody that may fight MPV, RSV
Jul. 17, 2014—New Vanderbilt-led research published in the Journal of Infectious Diseases has identified an antibody that shows promise in preventing and treating human metapneumovirus (MPV) and respiratory syncytial virus (RSV) — the two leading causes of respiratory infections in young children.
Discovery may pave way for RSV vaccine
Feb. 5, 2014—Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.
VU researchers ‘goldsmith’ new RSV vaccine approach
Jul. 18, 2013—Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.
Study finds maternal diet may predict RSV severity
Mar. 4, 2013—An important predictor of the severity of respiratory syncytial virus (RSV) in infants may be what their mothers ate during pregnancy.
Cell entry ports for cold virus
Sep. 25, 2012—The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.
New therapeutic target for cold, flu viruses identified
Aug. 9, 2012—Viruses that cause acute respiratory infections — such as human metapneumovirus (HMPV) and flu — impair a set of immune system cells that should clear the virus from the lungs. Now, Vanderbilt University investigators have discovered the signaling pathway that disables these immune cells.
